May 3, 2018 / 12:42 PM / 24 days ago

BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer

May 3 (Reuters) - Bristol-Myers Squibb Co:

* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL-MYERS SQUIBB’S TYPE II VARIATION APPLICATION FOR OPDIVO PLUS YERVOY COMBINATION FOR TREATMENT OF FIRST-LINE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

* BRISTOL-MYERS SQUIBB CO - APPLICATION IS BASED ON DATA FROM PART 1 OF CHECKMATE -227, A GLOBAL PHASE 3 STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below